✦ LIBER ✦

Assessment of the Association Between Colchicine Therapy and Serious Adverse Events

✍ Scribed by Brittany A. Todd; Sarah J. Billups; Thomas Delate; Kara E. Canty; Amy B. Kauffman; Julia E. Rawlings; Theresa M. Wagner

Book ID: 118765802
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 163 KB
Volume: 32
Category: Article
ISSN: 0277-0008
DOI: 10.1002/phar.1125

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Statistical assessment of the associatio

Statistical assessment of the association between vaccination and rare adverse events post-licensure

✍ N.J. Andrews 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Assessment of Adverse Events Associated

Assessment of Adverse Events Associated With Triptans—Methods of Assessment Influence the Results

✍ Fred D. Sheftell; Michele Feleppa; Stewart J. Tepper; Alan M. Rapoport; Luciana 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Clinical review: Serious adverse events

Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

✍ Pashtoon M Kasi, Hussein A Tawbi, Chester V Oddis, Hrishikesh S Kulkarni 📂 Article 📅 2012 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 608 KB

Quality of Methods for Assessing and Rep

Quality of Methods for Assessing and Reporting Serious Adverse Events in Clinical Trials of Cancer Drugs

✍ Belknap, S M; Georgopoulos, C H; West, D P; Yarnold, P R; Kelly, W N 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 133 KB

Anti-CTLA-4 antibody therapy associated

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

✍ Troy Dillard; Chris G. Yedinak; Joshi Alumkal; Maria Fleseriu 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 406 KB

Myeloproliferative disorder therapy: ass

Myeloproliferative disorder therapy: assessment and management of adverse events—a cardiologist's perspective

✍ Dermot Kenny 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Although some cardiac effects, such as palpitations and tachycardia, occur commonly in healthy people, they have also been shown to be associated with agents used to treat the myeloproliferative disorders. Various strategies exist to prevent and manage cardiac effects and minimise their